Profile data is unavailable for this security.
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
- Revenue in USD (TTM)54.03m
- Net income in USD-412.78m
- Incorporated2007
- Employees539.00
- LocationAgios Pharmaceuticals Inc88 Sidney StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 649-8600
- Fax+1 (302) 655-5049
- Websitehttps://www.agios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.61bn | 26.00 | -- | 8.49 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.63bn | 317.00 | -- | 2.99 | -- | 19.36 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.63bn | 28.00 | -- | 3.37 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Novavax Inc | 1.12bn | 440.30m | 1.65bn | 749.00 | 4.19 | -- | 3.52 | 1.47 | 2.41 | 2.41 | 6.37 | -0.7858 | 0.821 | 7.20 | 10.46 | 1,499,972.00 | 32.17 | -28.14 | 78.45 | -190.63 | 93.50 | -- | 39.19 | -45.53 | 2.10 | 24.98 | 2.06 | -- | 64.69 | 18.76 | 334.83 | -- | -36.68 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.67bn | 123.00 | -- | 61.20 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.68bn | 123.00 | -- | 5.06 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.68bn | 60.00 | -- | 6.43 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Palvella Therapeutics Inc | 0.00 | -35.07m | 1.68bn | 14.00 | -- | 38.01 | -- | -- | -3.83 | -3.83 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -80.19 | -31.18 | -96.21 | -43.15 | -- | -- | -- | -122.22 | -- | -3.05 | 0.2929 | -- | -100.00 | -- | 28.97 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 54.03m | -412.78m | 1.71bn | 539.00 | -- | 1.43 | -- | 31.67 | -7.12 | -7.12 | 0.932 | 20.41 | 0.0365 | 0.2096 | 7.36 | 100,237.50 | -27.89 | -10.70 | -29.52 | -11.34 | 88.26 | -- | -764.01 | -516.35 | 11.06 | -- | 0.00 | -- | 48.03 | -- | -161.27 | -- | -21.96 | -- |
| Definium Therapeutics Inc | 0.00 | -183.79m | 1.71bn | 105.00 | -- | 5.11 | -- | -- | -2.06 | -2.06 | 0.00 | 3.36 | 0.00 | -- | -- | 0.00 | -49.52 | -52.67 | -57.73 | -60.64 | -- | -- | -- | -- | -- | -- | 0.1088 | -- | -- | -- | -69.12 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.74bn | 60.00 | -- | 6.18 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.74bn | 263.00 | -- | 5.51 | -- | 12.97 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Relay Therapeutics Inc | 15.36m | -276.48m | 1.75bn | 192.00 | -- | 3.00 | -- | 113.94 | -1.61 | -1.61 | 0.0895 | 3.26 | 0.0206 | -- | -- | 79,979.16 | -37.05 | -35.52 | -39.04 | -37.06 | -- | -- | -1,800.46 | -2,911.42 | -- | -- | 0.00 | -- | 53.44 | -28.58 | 18.13 | -- | -26.65 | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.75bn | 65.00 | -- | 3.67 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Pharvaris NV | 0.00 | -191.34m | 1.79bn | 108.00 | -- | 4.98 | -- | -- | -3.41 | -3.41 | 0.00 | 5.62 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
Data as of Mar 02 2026. Currency figures normalised to Agios Pharmaceuticals Inc's reporting currency: US Dollar USD
52.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 31 Dec 2025 | 5.16m | 8.85% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.14m | 8.81% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.13m | 7.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.11m | 5.33% |
| Armistice Capital LLCas of 31 Dec 2025 | 3.04m | 5.21% |
| Erste Asset Management GmbHas of 31 Dec 2025 | 2.80m | 4.81% |
| Erste Asset Management GmbH (Czech Republic)as of 30 Jun 2025 | 2.22m | 3.81% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.84m | 3.15% |
| Nomura Investment Management Business Trustas of 31 Dec 2025 | 1.70m | 2.92% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.41m | 2.42% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
